Rohto Ice

Rohto Ice Manufacturers

• Rohto Pharmaceutical Co Ltd
  

  ×

  Rohto Ice | Rohto Pharmaceutical Co Ltd

  

  ---

  put 1 or 2 drops in the affected eye(s) up to 4 times daily

  tightly snap on cap to seal

  Close
  No Recall

  More Info
• Rohto Pharmaceutical Co Ltd
  

  ×

  Rohto Ice | Fresenius Kabi Usa, Llc

  

  ---

  Dexamethasone sodium phosphate injection, 10 mg/mL– For intravenous and intramuscular injection only.

  Dexamethasone sodium phosphate injection can be given directly from the vial, or it can be added to Sodium Chloride Injection or Dextrose Injection and administered by intravenous drip.

  Solutions used for intravenous administration or further dilution of this product should be preservative free when used in the neonate, especially the premature infant.

  When it is mixed with an infusion solution, sterile precautions should be observed.  Since infusion solutions generally do not contain preservatives, mixtures should be used within 24 hours.

  DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT.

  Intravenous and Intramuscular Injection
  

  The initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated.  In less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required.

  The initial dosage should be maintained or adjusted until the patient’s response is satisfactory.  If a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy.

  After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.

  Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma).  During stress it may be necessary to increase dosage temporarily. 

  If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually.

  When the intravenous route of administration is used, dosage usually should be the same as the oral dosage.  In certain overwhelming, acute, life-threatening situations, however, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.  The slower rate of absorption by intramuscular administration should be recognized.

  Shock
  

  There is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive shock.  The following dosages of dexamethasone sodium phosphate injection have been suggested by various authors:

  Author

  Dosage

  Cavanagh1

  3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg

  
  

  Dietzman2

  2 to 6 mg/kg of body weight as a single intravenous injection

  
  

  Frank3

  40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists

  
  

  Oaks4

  40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists

  
  

  Schumer5

  1 mg/kg of body weight as a single intravenous injection

  Administration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours.

  Although adverse reactions associated with high dose, short-term corticosteroid therapy are uncommon, peptic ulceration may occur.

  Cerebral Edema
  

  Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside.  Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with 2 mg two or three times a day may be effective.

  Acute Allergic Disorders
  

  In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested:

  Dexamethasone sodium phosphate injection, first day, 4 or 8 mg intramuscularly.

  Dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day, 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit.

  This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases.

  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.

  Intravenous and Intramuscular Injection
  

  The initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated.  In less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required.

  The initial dosage should be maintained or adjusted until the patient’s response is satisfactory.  If a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy.

  After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.

  Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma).  During stress it may be necessary to increase dosage temporarily. 

  If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually.

  When the intravenous route of administration is used, dosage usually should be the same as the oral dosage.  In certain overwhelming, acute, life-threatening situations, however, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.  The slower rate of absorption by intramuscular administration should be recognized.

  Shock
  

  There is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive shock.  The following dosages of dexamethasone sodium phosphate injection have been suggested by various authors:

  Author

  Dosage

  Cavanagh1

  3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg

  
  

  Dietzman2

  2 to 6 mg/kg of body weight as a single intravenous injection

  
  

  Frank3

  40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists

  
  

  Oaks4

  40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists

  
  

  Schumer5

  1 mg/kg of body weight as a single intravenous injection

  Administration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours.

  Although adverse reactions associated with high dose, short-term corticosteroid therapy are uncommon, peptic ulceration may occur.

  Cerebral Edema
  

  Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside.  Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with 2 mg two or three times a day may be effective.

  Acute Allergic Disorders
  

  In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested:

  Dexamethasone sodium phosphate injection, first day, 4 or 8 mg intramuscularly.

  Dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day, 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit.

  This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases.

  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.

  Close
  No Recall

  More Info
• Rohto-mentholatum (Vietnam) Co. Ltd.
  

  ×

  Rohto Ice | Rohto-mentholatum (vietnam) Co. Ltd.

  

  ---

  put 1 or 2 drops in the affected eye(s) up to 4 times daily

  Other information

  • tightly snap on cap to seal

  Close
  No Recall

  More Info
• The Mentholatum Company
  

  ×

  Rohto Ice | The Mentholatum Company

  

  ---

  put 1 or 2 drops in the affected eye(s) up to 4 times daily

  Other Information

  • tightly snap on cap to seal

  Close
  No Recall

  More Info